Skip to main content
S&P 5007,757.17+0.58%DOW52,856.09+0.69%NASDAQ26,702.86+1.05%BTC$84,751.00+2.37%ETH$2,498.42+2.05%GOLD$4,159.50+0.41%OIL$97.71-0.11%
Smart Investors Daily
SID Premium
GR

NASDAQ · GRCE

Grace Therapeutics, Inc.

Healthcare · Biotechnology

$1.98

Down-$0.01 (-0.51%)

Updated Oct 21, 2026, 9:39 PM

SID Score

3.7/10

Composite research score

Smart Money

—

Institutional and insider signal

Market cap
47.49M
P/E ratio
-6.84
Dividend yield
0.00%
52-week range
$1.79 – $5.18
Volume
94.41K
Avg. volume
65.65K

Price performance · GRCE

GRCE price history

1M range · 21 trading sessions · Daily adjusted prices

Prices through Oct 20, 2026

GRCE closed at $1.98 after 21 trading sessions, down 7.48% for the selected period.

Last close
$1.98
Period change
-7.48%
Period low
$1.88
Period high
$2.16
Daily close
View OHLC price history
GRCE OHLC price history, latest 40 sessions
DateOpenHighLowCloseVolume
Oct 20, 2026$1.90$2.07$1.89$1.9894.41K
Oct 19, 2026$1.89$1.97$1.8216$1.8890.43K
Oct 16, 2026$1.9701$2.0305$1.85$1.89168.8K
Oct 15, 2026$1.91$1.97$1.89$1.95109.29K
Oct 14, 2026$1.97$2.01$1.8461$1.89177.97K
Oct 13, 2026$2.00$2.02$1.965$1.9953.84K
Oct 12, 2026$2.02$2.06$1.98$2.0250.63K
Oct 9, 2026$2.05$2.09$2.03$2.0837.79K
Oct 8, 2026$2.05$2.07$2.00$2.0452.59K
Oct 7, 2026$2.06$2.12$2.05$2.1084.25K
Oct 6, 2026$2.08$2.138$2.0508$2.065110.26K
Oct 5, 2026$2.04$2.08$2.01$2.0680.04K
Oct 2, 2026$2.04$2.07$2.00$2.07105.03K
Oct 1, 2026$2.11$2.13$1.98$2.04344.21K
Sep 30, 2026$2.135$2.16$2.10$2.1525.34K
Sep 29, 2026$2.11$2.15$2.0888$2.11130.16K
Sep 28, 2026$2.12$2.14$2.09$2.1258.75K
Sep 25, 2026$2.14$2.14$2.10$2.1280.18K
Sep 24, 2026$2.17$2.18$2.09$2.16106.34K
Sep 23, 2026$2.15$2.15$2.09$2.12193.89K
Sep 22, 2026$2.09$2.165$2.08$2.1471.12K

Latest GRCE news

The latest Smart Investors Daily articles mentioning GRCE.

Stock researchCompany · Overview

GRCE research

Overview

Company profile and research snapshot.

Company profile

Grace Therapeutics Inc is a late-stage specialty pharma company with drug delivery technologies and drug candidates addressing rare and orphan diseases. The company's lead drug candidate, GTx-104, is a novel injectable formulation of nimodipine for the treatment of a rare disease, aneurysmal subarachnoid hemorrhage. Other products are GTx-102 Ataxia-Telangiectasia, GTx-101 Postherpetic Neuralgia, and GTx-201.

Visit company website

Analyst outlook

Consensus and target data currently published for this company.

Consensus
Buy
Average target
$11.90
Implied upside
—
Analysts
8
GRCE recent ratings
DateFirmRatingTarget
Apr 24, 2026TD CowenBuy—
Feb 18, 2025HC Wainwright & Co.Buy—
Open full forecast

News briefing

No generated briefing is available yet.

Yahoo · Sep 3, 2026

Grace Therapeutics to Participate in the H.C. Wainright 28th Annual Global Investment Conference

PRINCETON, N.J., Sept. 03, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (Grace Therapeutics or the Company), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that Chief Executive Officer Prashant Kohli will participate and present in the H.C. Wainwright 28th Annual Global Investment Conference, to be held

Benzinga · Aug 13, 2026

Grace Therapeutics Q1 EPS $(0.91) Misses $(0.18) Estimate

Grace Therapeutics (NASDAQ:GRCE) reported quarterly losses of $(0.91) per share which missed the analyst consensus estimate of $(0.18) by 405.56 percent. This is a 333.33 percent decrease over losses of $(0.21) per

Yahoo · Aug 5, 2026

Grace Therapeutics Announces $10 Million Private Placement

Expected gross proceeds anticipated to extend the Company’s cash runway to the end of calendar 2028PRINCETON, N.J., Aug. 04, 2026 (GLOBE NEWSWIRE) -- Grace Therapeutics, Inc. (Nasdaq: GRCE) (“Grace Therapeutics” or “the Company”), a late-stage, biopharma company advancing GTx-104, a clinical-stage, novel, injectable formulation of nimodipine being developed for IV infusion to address significant unmet medical needs in aSAH patients, today announced that it has entered into a securities purchase

AI research layers

Interpretive context generated from the platform’s current data sources.

No results

AI research layers have not been published yet.

Featured By